2025 And Beyond: Another Look At Upcoming NDSRI Regulations
Source: SK pharmteco
Pharmaceutical companies are working to address the critical issue of nitrosamine NDSRIs in medications. After the FDA set strict acceptable intake (AI) limits in August 2023, manufacturers have been scrambling to meet the August 1, 2025, deadline for compliance. Many are now intensifying their efforts as the deadline draws near.
Review several significant developments that have emerged since the initial guidance.
access the Article!
Log In
Get unlimited access to:
Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue.
X
Enter your credentials below to log in. Not yet a member of Outsourced Pharma? Subscribe today.
Subscribe to Outsourced Pharma
X
Subscribe to Outsourced Pharma